Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?

Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma

(2013) Virginia Hernandez–Gea et al.   GASTROENTEROLOGY

Label-retaining liver cancer cells are relatively resistant to sorafenib

(2013) Hong-Wu Xin et al.   GUT

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma

(2012) Y-C Shen et al.   BRITISH JOURNAL OF CANCER

Obesity-related hepatocellular carcinoma: roles of risk factors altered in obesity

(2012) Chuan Shen   Frontiers in Bioscience-Landmark

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives

(2012) Christoph Welsch et al.   GUT

Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update

(2012) Angela Gauthier et al.   HEPATOLOGY RESEARCH

Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells

(2012) Marie-José Blivet-Van Eggelpoël et al.   JOURNAL OF HEPATOLOGY

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

(2012) King Pan Ng et al.   NATURE MEDICINE

Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma

(2011) Satoshi Shimizu et al.   INTERNATIONAL JOURNAL OF CANCER

Stem Cells in Hepatocarcinogenesis: Evidence from Genomic Data

(2010) Jens Marquardt et al.   SEMINARS IN LIVER DISEASE

Shifting paradigms: the seeds of oncogene addiction

(2009) Charles L Sawyers   NATURE MEDICINE

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE